PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
USANA Health Sciences, Inc. (USNA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US90328M1071

CUSIP

90328M107

Sector

Consumer Defensive

IPO Date

Jul 25, 1996

Highlights

Market Cap

$594.66M

EPS (TTM)

$2.83

PE Ratio

11.02

PEG Ratio

0.90

Total Revenue (TTM)

$640.89M

Gross Profit (TTM)

$514.42M

EBITDA (TTM)

$80.01M

Year Range

$30.13 - $50.32

Target Price

$51.50

Short %

5.20%

Short Ratio

4.80

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
USNA vs. SPY USNA vs. TRMD
Popular comparisons:
USNA vs. SPY USNA vs. TRMD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in USANA Health Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%SeptemberOctoberNovemberDecember2025February
-18.64%
9.82%
USNA (USANA Health Sciences, Inc.)
Benchmark (^GSPC)

Returns By Period

USANA Health Sciences, Inc. had a return of -10.59% year-to-date (YTD) and -34.91% in the last 12 months. Over the past 10 years, USANA Health Sciences, Inc. had an annualized return of -4.73%, while the S&P 500 had an annualized return of 11.26%, indicating that USANA Health Sciences, Inc. did not perform as well as the benchmark.


USNA

YTD

-10.59%

1M

-6.66%

6M

-18.64%

1Y

-34.91%

5Y*

-14.60%

10Y*

-4.73%

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of USNA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-9.25%-10.59%
2024-12.65%3.08%0.50%-14.39%14.64%-4.96%-1.41%-8.48%-7.10%-2.58%4.30%-6.85%-33.04%
20239.85%4.00%3.49%5.52%-8.59%3.91%2.97%-0.96%-8.83%-22.28%3.75%13.42%0.75%
2022-5.55%-7.92%-9.73%-3.51%-8.26%2.89%-3.79%-7.33%-13.13%-6.32%4.82%-3.34%-47.43%
20217.34%17.28%0.56%-7.80%17.50%-3.13%-6.99%1.85%-4.98%5.27%2.74%1.48%31.26%
2020-21.45%7.13%-12.62%54.47%-5.04%-13.33%10.55%-3.41%-6.07%2.72%-0.62%2.55%-1.85%
2019-0.54%-15.88%-14.85%-0.49%-15.19%12.22%-14.33%-0.12%0.62%8.36%-0.69%6.73%-33.28%
20180.81%2.34%12.43%22.88%10.85%-1.45%14.70%-0.23%-8.64%-2.93%4.58%-3.80%58.99%
20171.80%-6.82%-0.78%-1.30%13.28%-0.47%-10.92%3.68%-2.53%13.86%9.13%3.28%21.00%
2016-0.67%-11.17%7.72%-2.45%1.87%-7.64%23.23%-0.42%1.18%-7.12%-5.14%0.41%-4.19%
2015-4.44%2.01%11.11%2.36%12.62%6.69%-8.79%17.52%-8.51%-4.05%4.15%-4.62%24.52%
2014-20.79%22.21%2.97%-9.93%5.97%8.66%-18.29%14.38%0.86%54.74%-6.44%-3.80%35.74%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of USNA is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of USNA is 77
Overall Rank
The Sharpe Ratio Rank of USNA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of USNA is 55
Sortino Ratio Rank
The Omega Ratio Rank of USNA is 77
Omega Ratio Rank
The Calmar Ratio Rank of USNA is 2020
Calmar Ratio Rank
The Martin Ratio Rank of USNA is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for USANA Health Sciences, Inc. (USNA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for USNA, currently valued at -1.01, compared to the broader market-2.000.002.00-1.011.74
The chart of Sortino ratio for USNA, currently valued at -1.46, compared to the broader market-4.00-2.000.002.004.006.00-1.462.36
The chart of Omega ratio for USNA, currently valued at 0.83, compared to the broader market0.501.001.502.000.831.32
The chart of Calmar ratio for USNA, currently valued at -0.45, compared to the broader market0.002.004.006.00-0.452.62
The chart of Martin ratio for USNA, currently valued at -1.69, compared to the broader market-10.000.0010.0020.0030.00-1.6910.69
USNA
^GSPC

The current USANA Health Sciences, Inc. Sharpe ratio is -1.01. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of USANA Health Sciences, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-1.01
1.74
USNA (USANA Health Sciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


USANA Health Sciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-76.45%
-0.43%
USNA (USANA Health Sciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the USANA Health Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the USANA Health Sciences, Inc. was 94.90%, occurring on Apr 10, 2002. Recovery took 248 trading sessions.

The current USANA Health Sciences, Inc. drawdown is 76.45%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.9%Jul 28, 1998926Apr 10, 2002248Apr 3, 20031174
-77.67%Jul 26, 20181647Feb 12, 2025
-69.82%Feb 9, 2007519Mar 3, 20091058May 15, 20131577
-67.4%Aug 14, 1996174Apr 23, 1997233Mar 26, 1998407
-46.16%Aug 6, 2015130Feb 10, 2016539Apr 3, 2018669

Volatility

Volatility Chart

The current USANA Health Sciences, Inc. volatility is 9.67%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%SeptemberOctoberNovemberDecember2025February
9.67%
3.01%
USNA (USANA Health Sciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of USANA Health Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of USANA Health Sciences, Inc. compared to its peers in the Packaged Foods industry.


PE Ratio
20.040.060.080.0100.0120.011.0
The chart displays the price to earnings (P/E) ratio for USNA in comparison to other companies of the Packaged Foods industry. Currently, USNA has a PE value of 11.0. This PE value is considered to be low compared to the rest of the industry.
PEG Ratio
-100.0-50.00.00.9
The chart displays the price to earnings to growth (PEG) ratio for USNA in comparison to other companies of the Packaged Foods industry. Currently, USNA has a PEG value of 0.9. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for USANA Health Sciences, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab